Neurol. praxi. 2016;17(5):283-286 | DOI: 10.36290/neu.2016.059

Proton MR spectroscopy in neurooncology

MUDr. Martin Bulik1, MUDr. Tomáš Kazda2, doc. MUDr. Radim Jančálek, Ph.D.3
1 Klinika zobrazovacích metod LF MU a FN u sv. Anny v Brně
2 Klinika radiační onkologie LF MU a Masarykova onkologického ústavu, Brno
3 Neurochirurgická klinika LF MU a FN u sv. Anny v Brně

Proton MR spectroscopy provides the non-invasive assessment of metabolites in examined tissue, can be used to get intracranial neoplasms structural information, increases the specificity of structural magnetic resonance and may serve as an additional examination for evaluation of the response to treatment and decisions to change the treatment strategy as it is in diferentiation of posttreatment changes and recurrence after comlex oncologic treatment of glioma patients. Biochemic changes in glioma differ according to histology and tumor grading. The results of MR spectroscopy can be used for several indications in neurooncology. However, it is important to remember spectroscopy limitations and the necessity of an adequate institutional experience.

Keywords: magnetic resonance, spectroscopy, glioma

Published: November 7, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bulik M, Kazda T, Jančálek R. Proton MR spectroscopy in neurooncology. Neurol. praxi. 2016;17(5):283-286. doi: 10.36290/neu.2016.059.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bradac O, Vrana J, Jiru F, Kramar F, Netuka D, Hrabal P, Horinek D, de Lacy P, Benes V. Recognition of anaplastic foci within low-grade gliomas using MR spectroscopy. Br J Neurosurg. 2014; 28(5): 631-636. Go to original source... Go to PubMed...
    2. Bulik M, Jancalek R, Vanicek J, Skoch A, Mechl M. Potential of MR spectroscopy for assessment of glioma grading. Clin Neurol Neurosurg. 2013; 115(2): 146-153. Go to original source... Go to PubMed...
    3. Castillo M, Kwock L, Courvoisie HE, Hooper SR, Greenwood RS. Proton MR spectroscopy in psychiatric and neurodevelopmental childhood disorders: early experience. Neuroimaging Clin N Am. 1998; 8(4): 901-912. Go to PubMed...
    4. Crisi G. (1)H MR Spectroscopy of meningiomas at 3.0T: the role of glutamate-glutamine complex and glutathione. Neuroradiol J. 2011; 24(6): 846-853. Go to original source... Go to PubMed...
    5. Dowling C, Bollen AW, Noworolski SM, McDermott MW, Barbaro NM, Day MR, Henry RG, Chang SM, Dillon WP, Nelson SJ, Vigneron DB. Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimens. AJNR Am J Neuroradiol. 2001; 22(4): 604-612.
    6. Incidence zhoubných novotvarů v ČR v roce 2011. 204-10-15. Dostupný na http://www.uzis.cz/rychle-informace/zhoubne-nadory-roce-2011.
    7. Kazda T, Bulik M, Pospisil P, Lakomy R, Smrcka M, Slampa P, Jancalek R. Advanced MRI increases the diagnostic accuracy of recurrent glioblastoma: Single institution thresholds and validation of MR spectroscopy and diffusion weighted MR imaging. Neuroimage Clin. 2016; 11: 316-321. Go to original source... Go to PubMed...
    8. Lai PH, Li KT, Hsu SS, Hsiao CC, Yip CW, Ding S, Yeh LR, Pan HB. Pyogenic brain abscess: findings from in vivo 1.5-T and 11.7-T in vitro proton MR spectroscopy. AJNR Am J Neuroradiol. 2005; 26(2): 279-288.
    9. Law M, Yang S, Wang H, Babb JS, Johnson G, Cha S, Knopp EA, Zagzag D. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol. 2003; 24(10): 1989-1998.
    10. McKnight TR, von dem Bussche MH, Vigneron DB, Lu Y, Berger MS, McDermott MW, Dillon WP, Graves EE, Pirzkall A, Nelson SJ. Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. J Neurosurg. 2002; 97(4): 794-802. Go to original source... Go to PubMed...
    11. Server A, Josefsen R, Kulle B, Maehlen J, Schellhorn T, Gadmar ?, Kumar T, Haakonsen M, Langberg CW, Nakstad PH. Proton magnetic resonance spectroscopy in the distinction of high-grade cerebral gliomas from single metastatic brain tumors. Acta Radiol. 2010; 51(3): 316-25. Go to original source... Go to PubMed...
    12. Tedeschi G, Lundbom N, Raman R, Bonavita S, Duyn JH, Alger JR, Di Chiro G. Increased choline signal coinciding with malignant degeneration of cerebral gliomas: a serial proton magnetic resonance spectroscopy imaging study. J Neurosurg. 1997; 87(4): 516-524. Go to original source... Go to PubMed...
    13. Wagnerova D, Herynek V, Malucelli A, Dezortova M, Vymazal J, Urgosik D, Syrucek M, Jiru F, Skoch A, Bartos R, Sames M, Hajek M. Quantitative MR imaging and spectroscopy of brain tumours: a step forward? Eur Radiol. 2012; 22(11): 2307-2318. Go to original source... Go to PubMed...
    14. Wang Z, Sutton LN, Cnaan A, Haselgrove JC, Rorke LB, Zhao H, Bilaniuk LT, Zimmerman RA. Proton MR spectroscopy of pediatric cerebellar tumors. AJNR Am J Neuroradiol. 1995; 16(9): 1821-1833.
    15. Zhang J, Zhuang DX, Yao CJ, Lin CP, Wang TL, Qin ZY, Wu JS. Metabolic approach for tumor delineation in glioma surgery: 3D MR spectroscopy image-guided resection. J Neurosurg. 2015 Dec 4: 1-9.

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.